Allarity Received A "Wells Notice" From SEC Relating To Its Disclosures Regarding Meetings With The FDA Regarding NDA For Dovitinib Or Dovitinib-DRP, Which Was Submitted In 2021. Allarity's Three Former Officers Have Received The Notice

7/22/24 8:02:19 AM ET

$ALLR

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALLR alert in real time by email

Current Cash Balance of $20 million Expected to Provide Runway Into 2026
Allarity to Pause Use of ATM
Cap Table Successfully Cleaned Up
Allarity's Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit

Get the next $ALLR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALLR

Date	Price Target	Rating	Analyst

More analyst ratings

$ALLR
Leadership Updates

Live Leadership Updates

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio
11/14/24 8:00:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk's U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced seve
10/3/24 8:00:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement Grants Boston (September 13, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the appointment of Alex Epshinsky as the Company's new Chief Financial Officer (CFO), and that the Company has granted equity awards on September 12, 2024 as a material inducement to the employment of Mr. Epshinsky. Mr. Epshinsky is a Chartered Public Accountant (CPA) and brings nearly a decade of financial leadership experience in the biotech and
9/13/24 8:45:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care

$ALLR
Press Releases

Fastest customizable press release news feed in the world

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Boston (February 6, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing the clinical development of stenoparib toward FDA approval in advanced ovarian cancer. With this new phase 2 protocol, Allarity will capitalize and expand on the ongoing phase 2 clinical trial data to optimize the dose of stenoparib and to refine the DRP® patient selection crit
2/6/25 8:00:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Boston (January 30, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, has filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC") regarding its agreement in principle with the SEC staff to resolve the previously disclosed SEC investigation. The settlement relates to the Company's disclosures, occurring during or prior to fiscal year 2022, regarding meetings with the United States Food and Drug Administration (the "FDA") concerning our New Drug Application ("NDA") for Dovitini
1/30/25 8:00:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development toward FDA approval Expansion of Allarity Medical Laboratory into revenue-generating services for external biotech clientsContinued focus on advancing stenoparib to address critical unmet needs in ovarian cancer Boston (November 18, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today
11/18/24 8:00:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care

$ALLR
Financials

Live finance-specific insights

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s
5/14/24 4:01:00 PM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity's cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses:
11/15/22 4:01:00 PM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib
Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or the "Company"), a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc. ("Oncoheroes"), a clini
1/3/22 8:00:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care

Allarity Received A "Wells Notice" From SEC Relating To Its Disclosures Regarding Meetings With The FDA Regarding NDA For Dovitinib Or Dovitinib-DRP, Which Was Submitted In 2021. Allarity's Three Former Officers Have Received The Notice

Chat with this insight

Recent Analyst Ratings for
$ALLR

$ALLR
Leadership Updates

Live Leadership Updates

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$ALLR
Press Releases

Fastest customizable press release news feed in the world

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

$ALLR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.

SEC Form SC 13G filed by Allarity Therapeutics Inc.

SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

$ALLR
Financials

Live finance-specific insights

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

$ALLR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form 4 filed by Director Vazzano Joseph Walter

Amendment: SEC Form 4 filed by Director Benjamin Laura

Amendment: SEC Form 4 filed by Director Mclaughlin Gerald W.

$ALLR
SEC Filings

Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events

Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Allarity Received A "Wells Notice" From SEC Relating To Its Disclosures Regarding Meetings With The FDA Regarding NDA For Dovitinib Or Dovitinib-DRP, Which Was Submitted In 2021. Allarity's Three Former Officers Have Received The Notice

Chat with this insight

Recent Analyst Ratings for $ALLR

$ALLR Leadership Updates

Live Leadership Updates

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$ALLR Press Releases

Fastest customizable press release news feed in the world

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

$ALLR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.

SEC Form SC 13G filed by Allarity Therapeutics Inc.

SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

$ALLR Financials

Live finance-specific insights

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

$ALLR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form 4 filed by Director Vazzano Joseph Walter

Amendment: SEC Form 4 filed by Director Benjamin Laura

Amendment: SEC Form 4 filed by Director Mclaughlin Gerald W.

$ALLR SEC Filings

Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events

Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Recent Analyst Ratings for
$ALLR

$ALLR
Leadership Updates

$ALLR
Press Releases

$ALLR
Large Ownership Changes

$ALLR
Financials

$ALLR
Insider Trading

$ALLR
SEC Filings